Current Advance in Targeted Treatment and Immunotherapy for BRAF-mutant
Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2021.101.29
- Author:
Na LI
1
;
Yanjun XU
2
;
Yun FAN
2
Author Information
1. Wenzhou Medical University, Wenzhou 325035, China.
2. Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of
Sciences, Hangzhou 310022, China.
- Publication Type:Review
- Keywords:
BRAF;
Immunotherapy;
Lung neoplasms;
Targeted therapy
- MeSH:
Carcinoma, Non-Small-Cell Lung/genetics*;
Humans;
Immunotherapy;
Lung Neoplasms/genetics*;
Mutation;
Proto-Oncogene Proteins B-raf/genetics*
- From:
Chinese Journal of Lung Cancer
2021;24(10):714-722
- CountryChina
- Language:Chinese
-
Abstract:
With the development of precision medicine, therapies of targeting driver genes have significantly prolonged survival in advanced non-small cell lung cancer (NSCLC) patients. Among them, BRAF gene mutation is relatively rare, and the traditional regimen follows the treatment plan of NSCLC without driver gene mutation, which is far from meeting the clinical needs. In recent years, targeted therapy for NSCLC patients with BRAF V600E mutations has shown good efficacy when we are still exploring the better targeted therapies for other BRAF-mutated subtypes. Immunotherapy also showed positive antitumor activity in V600E and non-V600E subtypes of BRAF-mutated NSCLC. This article reviewed the progress of immunological and targeted therapy for patients with BRAF-mutated NSCLC.
.
